Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model
- Open Access
- 26.12.2022
- Correction
Erschienen in:
Correction to: Cancer Immunology, Immunotherapy https://doi.org/10.1007/s00262-022-03318-x
In the online published article, the affiliation details for Authors Tianyun Qiao, Yangbo Feng and Yong Han were given as:
Anzeige
Department of Thoracic Surgery, Air Force Specialty Medical Center, Fourth Military Medical University, Xi’an 710032, China
but should have been
Department of Thoracic Surgery, Air Force Medical Center, Beijing 100142, China
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
